Welcome to LookChem.com Sign In|Join Free
  • or
2-(4-ethoxycarbonyl-phenylimino)-thiazolidin-4-one is a chemical compound with the molecular formula C12H12N2O3S. It belongs to the thiazolidin-4-one class of compounds and is commonly used in pharmaceutical research and drug development. 2-(4-ethoxycarbonyl-phenylimino)-thiazolidin-4-one is known for its potential as an anti-inflammatory and anti-cancer agent in preclinical studies. Its unique molecular structure and biological activity make it an important target for further research and potential drug discovery. The ethoxycarbonyl and phenylimino groups in the compound contribute to its pharmacological properties, and it is being studied for its potential therapeutic applications in various disease conditions.

17823-28-8

Post Buying Request

17823-28-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

17823-28-8 Usage

Uses

Used in Pharmaceutical Research:
2-(4-ethoxycarbonyl-phenylimino)-thiazolidin-4-one is used as a research compound for its potential anti-inflammatory and anti-cancer properties. It is being studied to understand its mechanism of action and to develop new therapeutic strategies for treating various diseases.
Used in Drug Development:
In the pharmaceutical industry, 2-(4-ethoxycarbonyl-phenylimino)-thiazolidin-4-one is used as a lead compound in drug development. Its unique structure and biological activity make it a promising candidate for the creation of new drugs with potential therapeutic applications.
Used in Preclinical Studies:
2-(4-ethoxycarbonyl-phenylimino)-thiazolidin-4-one is used as a test compound in preclinical studies to evaluate its efficacy and safety as a potential therapeutic agent. These studies help to determine the compound's potential for further development into a viable drug for clinical use.
Used in Disease Treatment Research:
2-(4-ethoxycarbonyl-phenylimino)-thiazolidin-4-one is used as a potential therapeutic agent in research aimed at treating various diseases. Its anti-inflammatory and anti-cancer properties are of particular interest, and ongoing studies are exploring its effectiveness in treating these conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 17823-28-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,8,2 and 3 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 17823-28:
(7*1)+(6*7)+(5*8)+(4*2)+(3*3)+(2*2)+(1*8)=118
118 % 10 = 8
So 17823-28-8 is a valid CAS Registry Number.

17823-28-8Relevant academic research and scientific papers

Heterocyclic tautomerism: Reassignment of two crystal structures of 2-amino-1,3-thia-zolidin-4-one derivatives

Gzella, Andrzej K.,Kowiel, Marcin,Suse?, Aneta,Wojtyra, Magdalena N.,Lesyk, Roman

, p. 812 - 816 (2014)

The structures of 5-(2-hy-droxy-ethyl)-2-[(pyridin-2-yl)amino]-1,3-thia- zolidin-4-one, C10H11N3O2S, (I), and ethyl 4-[(4-oxo-1,3-thia-zolidin-2-yl) amino]-benzoate, C12H12N2O3S, (II), which are identical to the entries with refcodes GACXOZ [Váňa et al. (2009). J. Heterocycl. Chem. 46, 635-639] and HEGLUC [Behbehani & Ibrahim (2012). Mol-ecules, 17, 6362-6385], respectively, in the Cambridge Structural Database [Allen (2002). Acta Cryst. B58, 380-388], have been redetermined at 130 K. This structural study shows that both investigated compounds exist in their crystal structures as the tautomer with the carbonyl-imine group in the five-membered heterocyclic ring and an exocyclic amine N atom, rather than the previously reported tautomer with a secondary amide group and an exocyclic imine N atom. The physico-chemical and spectroscopic data of the two investigated compounds are the same as those of GACXOZ and HEGLUC, respectively. In the thia-zolidin-4-one system of (I), the S and chiral C atoms, along with the hy-droxy-ethyl group, are disordered. The thia-zolidin-4-one fragment takes up two alternative locations in the crystal structure, which allows the mol-ecule to adopt R and S configurations. The occupancy factors of the disordered atoms are 0.883 (2) (for the R configuration) and 0.117 (2) (for the S configuration). In (I), the main factor that determines the crystal packing is a system of hydrogen bonds, involving both strong N - H?N and O - H?O and weak C - H?O hydrogen bonds, linking the mol-ecules into a three-dimensional hydrogen-bond network. On the other hand, in (II), the mol-ecules are linked via N - H?O hydrogen bonds into chains.

4-Thiazolidinones in heterocyclic synthesis: Synthesis of novel enaminones, azolopyrimidines and 2-arylimino-5-arylidene-4-thiazolidinones

Behbehani, Haider,Ibrahim, Hamada Mohamed

experimental part, p. 6362 - 6385 (2012/08/28)

The 4-thiazolidinones 3a-d were used as a key intermediates for the synthesis of 2-arylimino-5-arylidene-4-thiazolidinones derivatives 7a-p via nucleophilic addition reactions with the arylidene malononitrile. Moreover the 4-thiazolidinones 3a and 3c condensed with the DMF-DMA to form the corresponding enamines 8 and 9 depending on the reaction conditions. Otherwise the 4-thiazolidinone 3b reacts regioselectively with DMF-DMA to afford the enaminones 10 and 11, respectively. The latter reacts with many heterocyclic amines affording polyfunctionally substituted fused pyrimidine derivatives 13-18. The enamine 8b was also reacted with the 3-amino-1,2,4-triazole to afford the acyclic product 19, which could not be further cyclized to the corresponding tricyclic system 20. Moreover the 4-thiazolidinone 3c reacted with the benzenediazonium chloride to afford the arylhydrazones 12. The X-ray single crystal technique was employed in this study for structure elucidation and Z/E potential isomerism configuration determination. The X-ray crystallographic analyses of eight products could be obtained, thus establishing with certainty the structures proposed in this work.

Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells

Zhou, Hongyu,Wu, Shuhong,Zhai, Shumei,Liu, Aifeng,Sun, Ying,Li, Rongshi,Zhang, Ying,Ekins, Sean,Swaan, Peter W.,Fang, Bingliang,Zhang, Bin,Yan, Bing

, p. 1242 - 1251 (2008/12/23)

Ten cytoselective compounds have been identified from 372 thiazolidinone analogues by applying iterative library approaches. These compounds selectively killed both non-small cell lung cancer cell line H460 and its paclitaxel-resistant variant H460taxR at an IC50 between 0.21 and 2.93 μM while showing much less toxicity to normal human fibroblasts at concentrations up to 195 μM. Structure-activity relationship studies revealed that (1) the nitrogen atom on the 4-thiazolidinone ring (ring B in Figure 1) cannot be substituted, (2) several substitutions on ring A are tolerated at various positions, and (3) the substitution on ring C is restricted to the -NMe2 group at the 4-position. A pharmacophore derived from active molecules suggested that two hydrogen bond acceptors and three hydrophobic regions were common features. Activities against P-gp-overexpressing and paclitaxel-resistant cell line H460taxR and modeling using a previously validated P-gp substrate pharmacophore suggested that active compounds were not likely P-gp substrates.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 17823-28-8